晚期肉瘤样肾细胞癌治疗进展  

The research progress in the treatment of advanced sarcomatoid renal cell carcinoma

作　　者：王柯若 吴俣祺 李刚[1] Wang Keruo;Wu Yuqi;Li Gang(Department of Urology,The Second Hospital of Tianjin Medical University,Tianjin 300211,China)

机构地区：[1]天津医科大学第二医院泌尿外科,天津300211

出　　处：《中华泌尿外科杂志》2022年第3期237-240,共4页Chinese Journal of Urology

摘　　要：肉瘤样肾细胞癌是一种伴有肉瘤样去分化特征的高度恶性肿瘤,其进展快、病死率高,预后较差。研究结果表明,晚期肉瘤样肾细胞癌患者行减瘤手术、单药化疗或靶向治疗效果不佳。随着对肉瘤样肾细胞癌发病机制及分子生物学特征研究的深入,发现其PD-1和PD-L1表达水平高于其他病理亚型,因此免疫检查点抑制剂组合疗法和免疫治疗联合靶向治疗已经成为其一线治疗方案。本文主要就晚期肉瘤样肾细胞癌手术、化疗、靶向治疗、免疫治疗等最新治疗方法进行综述。Sarcomatoid renal cell carcinoma is a highly malignant tumor with sarcomatoid dedifferentiation,which has rapid progression,high mortality rate and poor prognosis.Studies have shown that cytoreductive surgery,chemotherapy or targeted therapy are not effective to patients with advanced sarcomatoid renal cell carcinoma.With the further study of pathogenesis and molecular biological characteristics of sarcomatoid renal cell carcinoma,it is found that the expression levels of PD-1 and PD-L1 in it are higher than those of other subtypes,so the combination of immune checkpoint inhibitors and immunotherapy combined with targeted therapy have become the first-line therapy.This article mainly reviews the latest treatments for advanced sarcomatoid renal cell carcinoma,including surgery,chemotherapy,targeted drugs,immunotherapy and so on.

关 键 词：癌 肾细胞 肉瘤样 治疗方法 研究进展 转移 免疫治疗 

分 类 号：R737.11[医药卫生—肿瘤]